SCHEMBL13879433

SCHEMBL13879433

O=C1NC(c2ccccc2)C(=O)N1c1cc(Cl)cc(Cl)c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AR P10275 1/20 0.60
LMNA P02545 3/20 0.47
ADORA3 P0DMS8 1/20 0.47
GAA P10253 2/20 0.45
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
ALDH1A1 P00352 1/20 0.45
MAPT P10636 1/20 0.45
ALOX15 P16050 1/20 0.45
ALOX12 P18054 1/20 0.45
HSD17B10 Q99714 1/20 0.45
ITGA4 P13612 1/20 0.43
ITGB7 P26010 1/20 0.43
S1PR1 P21453 1/20 0.41
S1PR3 Q99500 1/20 0.41
DRD2 P14416 1/20 0.41
DRD4 P21917 1/20 0.41
ABL1 P00519 1/20 0.37
RIN1 Q13671 1/20 0.37
TSHR P16473 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13879419 0.89 AR (0.62) ARLMNAADORA3GAAMEN1
SCHEMBL845936 0.86 AR (0.61) ARLMNAADORA3GAAMEN1
SCHEMBL4437165 0.81 LMNA (0.54) ARLMNAADORA3MEN1KMT2A
SCHEMBL4439842 0.81 LMNA (0.54) ARLMNAADORA3MEN1KMT2A
SCHEMBL4439021 0.81 LMNA (0.54) ARLMNAADORA3MEN1KMT2A
SCHEMBL17338881 0.75 ALDH1A1 (0.48) LMNAGAAMEN1KMT2AALDH1A1
SCHEMBL22898500 0.75 ALDH1A1 (0.48) LMNAGAAMEN1KMT2AALDH1A1
SCHEMBL17347124 0.75 ALDH1A1 (0.48) LMNAGAAMEN1KMT2AALDH1A1
SCHEMBL17347068 0.75 ALDH1A1 (0.48) LMNAGAAMEN1KMT2AALDH1A1
SCHEMBL18787456 0.75 ALDH1A1 (0.48) LMNAGAAMEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090099186-A1 INHIBITORS OF VIRAL REPLICATION INTERMUNE, INC. 2009-04-16 US disclosed
US-20090099186-A1 INHIBITORS OF VIRAL REPLICATION INTERMUNE, INC. 2009-04-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090099186-A1 INHIBITORS OF VIRAL REPLICATION EIF2AK2, HAVCR2, RTF2 AR 4274/4885LMNA 2024/4885ADORA3 4469/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.